Drug may shield kidneys from dye harm in ICU
NCT ID NCT07561801
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether pentoxifylline, a drug that improves blood flow, can prevent kidney damage caused by contrast dye used in medical imaging. The trial included 70 adults with chronic kidney disease who were in the intensive care unit and needed contrast dye. Researchers measured how many patients developed contrast-induced nephropathy, changes in kidney function, length of ICU stay, and need for dialysis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tanta University
Tanta, El-Gharbia, 31527, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Could a phone app be the key to managing kidney disease?
- A new pill aims to slow kidney failure and save lives
- AI takes on kidney disease: a new model to forecast Who's at risk